127 related articles for article (PubMed ID: 38762686)
1. Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues.
Yang L; Li X; Zhao L; Hu W; Qian Y
Mol Divers; 2024 May; ():. PubMed ID: 38762686
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Development of Dolastatin 10-Derived Antibody Drug Conjugate Anticancer Drugs.
Singh SB
J Nat Prod; 2022 Mar; 85(3):666-687. PubMed ID: 35072477
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications.
Akaiwa M; Martin T; Mendelsohn BA
ACS Omega; 2018 May; 3(5):5212-5221. PubMed ID: 30023909
[TBL] [Abstract][Full Text] [Related]
4. Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery.
Kim J; Kim JS; Min KH; Kim YH; Chen X
Bioengineering (Basel); 2021 Mar; 8(4):. PubMed ID: 33805342
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.
Dugal-Tessier J; Barnscher SD; Kanai A; Mendelsohn BA
J Nat Prod; 2017 Sep; 80(9):2484-2491. PubMed ID: 28885014
[TBL] [Abstract][Full Text] [Related]
6. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
7. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives.
Akaiwa M; Dugal-Tessier J; Mendelsohn BA
Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527
[TBL] [Abstract][Full Text] [Related]
9. Current Status: Site-Specific Antibody Drug Conjugates.
Schumacher D; Hackenberger CP; Leonhardt H; Helma J
J Clin Immunol; 2016 May; 36 Suppl 1():100-7. PubMed ID: 27003914
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
11. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.
Maderna A; Doroski M; Subramanyam C; Porte A; Leverett CA; Vetelino BC; Chen Z; Risley H; Parris K; Pandit J; Varghese AH; Shanker S; Song C; Sukuru SC; Farley KA; Wagenaar MM; Shapiro MJ; Musto S; Lam MH; Loganzo F; O'Donnell CJ
J Med Chem; 2014 Dec; 57(24):10527-43. PubMed ID: 25431858
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.
Park MH; Lee BI; Byeon JJ; Shin SH; Choi J; Park Y; Shin YG
Molecules; 2019 Jul; 24(15):. PubMed ID: 31362431
[TBL] [Abstract][Full Text] [Related]
13. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
Inoue K; Mochizuki T; Kasamori N; Komori T
Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.
Kalinovsky DV; Kibardin AV; Kholodenko IV; Svirshchevskaya EV; Doronin II; Konovalova MV; Grechikhina MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764367
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into the Pharmacophore of Vinca Domain Inhibitors of Microtubules.
Wang Y; Benz FW; Wu Y; Wang Q; Chen Y; Chen X; Li H; Zhang Y; Zhang R; Yang J
Mol Pharmacol; 2016 Feb; 89(2):233-42. PubMed ID: 26660762
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
[TBL] [Abstract][Full Text] [Related]
18. Dual-mechanistic antibody-drug conjugate
Nilchan N; Li X; Pedzisa L; Nanna AR; Roush WR; Rader C
Antib Ther; 2019 Oct; 2(4):71-78. PubMed ID: 31930187
[TBL] [Abstract][Full Text] [Related]
19. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
[TBL] [Abstract][Full Text] [Related]
20. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
